Dr. Reddy's Laboratories Ltd., specializes in Pharmaceuticals within the Healthcare sector.
Dr. Reddy's Laboratories Ltd.,, with Security Code 500124, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Date Begin | Date End | Net Sales | Net Profit | Total Income | Diluted EPS for continuing operation | Other Expenses | Other Income | Depreciation and amortisation expense | Profit (+)/ Loss (-) from Ordinary Activities before Tax |
|---|---|---|---|---|---|---|---|---|---|
| 2024-01-01 | 2024-03-31 | 71,138.00 | 13,098.00 | 73,113.00 | 78.53 | -19,242.00 | 1,975.00 | -3,677.00 | 16,017.00 |
| 2024-01-01 | 2024-03-31 | 51,048.00 | 10,348.00 | 53,175.00 | 62.04 | -15,187.00 | 2,127.00 | -2,462.00 | 13,392.00 |
| 2023-10-01 | 2023-12-31 | 41,030.00 | 4,752.00 | 43,306.00 | 28.50 | - | 2,276.00 | -2,464.00 | 6,319.00 |
| 2023-10-01 | 2023-12-31 | 72,368.00 | 13,809.00 | 74,530.00 | 82.81 | - | 2,162.00 | -3,735.00 | 18,264.00 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 13% |
| 3 Years: | 13% |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 28% |
| 3 Years: | 33% |
| TTM: | 65% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 20% |
| 3 Years: | 5% |
| 1 Year: | 24% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 13% |
| 3 Years: | 14% |
| TTM: | 14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 25% |
| 3 Years: | 42% |
| TTM: | 21% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 20% |
| 3 Years: | 5% |
| 1 Year: | 24% |
Dr. Reddy’s Laboratories Ltd. (DRL) has entered into a definitive agreement to acquire the oncology portfolio of privately held Nimbus Therapeutics, Inc., a clinical-stage oncology company focused on the development of novel immunotherapies. The acquisition will strengthen DRL’s position in the oncology therapeutic area with the addition of three promising clinical-stage assets and a robust preclinical pipeline.
Dr. Reddy’s Laboratories Ltd. (DRL) reported its financial results for the third quarter and nine months ended December 31, 2023. The Company delivered a strong performance across its businesses, driven by robust growth in the Pharmaceutical Services and Active Pharmaceutical Ingredients (APIs) segments.
Dr. Reddy’s Laboratories Ltd. (DRL) has announced the launch of Mometazole Injection in the United States market. Mometazole is indicated for the treatment of acute exacerbations of asthma in patients 12 years of age and older.
